Jacobs Levy Equity Management Inc. Purchases Shares of 357,248 Stoke Therapeutics, Inc. $STOK

Key Points

• Jacobs Levy Equity Management Inc. acquired a new stake in Stoke Therapeutics, purchasing 357,248 shares valued at approximately $2.4 million, representing 0.65% ownership of the company.
• A variety of institutional investors have also increased their stakes in Stoke Therapeutics, with notable transactions including a new position worth $35 million from Toronto Dominion Bank.
• Stoke Therapeutics recently reported quarterly earnings, exceeding expectations with a loss of $0.40 per share against a consensus estimate of $0.57, alongside revenue of $13.82 million, which fell short of the $31.51 million estimate.

Jacobs Levy Equity Management Inc. purchased a new stake in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 357,248 shares of the company's stock, valued at approximately $2,376,000. Jacobs Levy Equity Management Inc. owned 0.65% of Stoke Therapeutics as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of STOK. GAMMA Investing LLC raised its position in shares of Stoke Therapeutics by 1,842.0% in the first quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock valued at $36,000 after purchasing an additional 5,084 shares during the period. AlphaQuest LLC bought a new stake in Stoke Therapeutics during the 1st quarter worth approximately $72,000. US Bancorp DE increased its holdings in Stoke Therapeutics by 9,743.9% during the 1st quarter. US Bancorp DE now owns 11,222 shares of the company's stock worth $75,000 after acquiring an additional 11,108 shares during the period. Fox Run Management L.L.C. bought a new stake in Stoke Therapeutics during the 1st quarter worth approximately $92,000. Finally, Russell Investments Group Ltd. bought a new stake in Stoke Therapeutics during the 1st quarter worth approximately $107,000.

Analyst Ratings Changes

STOK has been the topic of a number of analyst reports. Wedbush upped their target price on shares of Stoke Therapeutics from $16.00 to $22.00 and gave the stock an "outperform" rating in a report on Wednesday, August 13th. Chardan Capital reaffirmed a "buy" rating and set a $24.00 target price on shares of Stoke Therapeutics in a report on Wednesday, August 13th. Jefferies Financial Group began coverage on shares of Stoke Therapeutics in a report on Friday, July 18th. They set a "buy" rating and a $30.00 target price on the stock. BTIG Research set a $28.00 price target on shares of Stoke Therapeutics and gave the stock a "buy" rating in a report on Monday, August 18th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $22.00 price target on shares of Stoke Therapeutics in a report on Tuesday, July 1st. Two research analysts have rated the stock with a Strong Buy rating and seven have given a Buy rating to the company's stock. According to MarketBeat, Stoke Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $25.57.

Stoke Therapeutics Stock Down 1.0%

Shares of Stoke Therapeutics stock traded down $0.24 during trading on Tuesday, reaching $23.16. The company's stock had a trading volume of 809,785 shares, compared to its average volume of 894,539. Stoke Therapeutics, Inc. has a 52-week low of $5.35 and a 52-week high of $24.60. The company has a market cap of $1.27 billion, a price-to-earnings ratio of 27.25 and a beta of 1.14. The firm's 50-day moving average is $16.50 and its two-hundred day moving average is $11.76.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.57) by $0.17. Stoke Therapeutics had a net margin of 26.25% and a return on equity of 18.32%. The company had revenue of $13.82 million during the quarter, compared to analysts' expectations of $31.51 million. On average, equities research analysts anticipate that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Insider Activity

In other news, insider Barry Ticho sold 5,501 shares of the company's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $19.87, for a total value of $109,304.87. Following the completion of the sale, the insider owned 18,469 shares of the company's stock, valued at approximately $366,979.03. This represents a 22.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Edward M. Md Kaye sold 45,996 shares of the stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $20.13, for a total transaction of $925,899.48. Following the sale, the director directly owned 91,585 shares of the company's stock, valued at $1,843,606.05. The trade was a 33.43% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 107,719 shares of company stock valued at $2,063,359. Corporate insiders own 9.50% of the company's stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.